NNC6019-0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial
Session:
Amyloidosis and aortic stenosis
Topic:
Infiltrative Myocardial Disease
Speaker:
Professor M. Fontana (London, GB)
Event:
ESC Congress 2022
Congress Presentation
6 more presentations in this session
Access the full session
About the event
